Recent investigations have focused on the overlap of GLP|GIP|glucagon receptor activator therapies and DA communication. While GCGR agonists are commonly employed for LL-37 managing type 2 diabetes, their potential effects on reinforcement circuits, specifically governed by DA pathways, are receiving significant attention. This report provides a su